Capox
Capox 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
9 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bristol-Myers Squibb
- Shandong Provincial Hospital
- Fudan University
- Ruijin Hospital
- Sun Yat-sen University
- Dechang Diao
- Sixth Affiliated Hospital, Sun Yat-sen University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、South Korea、日本、Argentina、澳大利亚、奥地利、比利时、Brazil、加拿大、Chile、法国
正在招募患者的 Capox 研究
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
II 期招募中中国NCT07284992MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
II 期招募中中国NCT06840665SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis
II 期招募中中国NCT07384234Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
III 期招募中中国NCT07528209Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）
II 期招募中中国NCT07005570Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
II 期招募中中国NCT06923345Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
II 期招募中中国NCT06848842A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
II 期招募中中国NCT07562490Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
II 期招募中中国NCT05914389Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
III 期招募中中国NCT07686640SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
I 期招募中美国NCT05412082Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
III 期招募中South KoreaNCT05534087Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
II 期招募中中国NCT06949111Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
III 期招募中日本NCT04288999A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
III 期招募中美国Argentina澳大利亚奥地利NCT06764875A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
III 期招募中中国NCT07315750Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer
III 期招募中中国NCT03125980Induction Chemotherapy for Locally Recurrent Rectal Cancer
III 期招募中比利时荷兰挪威PortugalNCT04389086A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
III 期招募中美国澳大利亚比利时BrazilNCT06901531A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
I 期 / II 期招募中中国NCT07327229Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
II 期招募中荷兰NCT05177133A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
II 期招募中中国NCT07669220Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
II 期招募中中国NCT05972655Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
II 期招募中中国NCT07689851
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。